Short report: Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

30Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months). Copyright © 2011 by The American Society of Tropical Medicine and Hygiene.

Cite

CITATION STYLE

APA

Amato, V. S., Tuon, F. F., Camargo, R. A., Souza, R. M., Santos, C. R., & Nicodemo, A. C. (2011). Short report: Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? American Journal of Tropical Medicine and Hygiene, 85(5), 818–819. https://doi.org/10.4269/ajtmh.2011.11-0287

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free